Anti-inflammatory activity of chondroitin sulfate

      This paper is only available as a PDF. To read, Please Download here.


      The pharmacokinetics of chondroitin sulfate (CS, Condrosulf®, IBSA, Lugano, Switzerland) were investigated in rats and in healthy volunteers using CS tritiated at the reducing end and CS labeled with 131I or 99mTc respectively. A rapid absorption of orally administered CS is observed in rats and in humans when the drug is dissolved in water. Lower and delayed absorption is observed when CS is administered in gastroresistant capsules. The absolute bio-availability is 15 and 12% for rats and humans respectively. The CS shows a tropism for cartilagineous tissues in rats and for knee tissues in humans as demonstrated by scintigraphic analysis with 99mTc-CS. Monomers, oligo and polysaccharides produced by enzymatic hydrolysis of CS appear in the blood and tissues together with native CS. The effects of partially depolymerized (m.m. 3 to 15 kD) and desulfated fractions on human leukocytes were investigated. CS and its fractions inhibit the directional chemotaxis induced by zymosan-activated serum, are able to decrease the phagocytosis and the release of lysozyme induced by zymosan and to protect the plasma membrane from oxygen reactive species. In rats the oral administration of CS significantly decreases granuloma formation due to sponge implants and cell migration and lysosomal enzyme release in carrageenan pleurisy. Compared with nonsteroidal anti-inflammatory drugs (indomethacin ibuprofen), CS appears to be more effective on cellular events of inflammation than on edema formation. It is noteworthy that CS is devoid of dangerous effects on the stomach, platelets and kidneys. In synovial fluid of patients requiring joint aspiration, treated orally for 10 days with CS (800 mg/day) the hyaluronate concentration and the intrinsic viscosity significantly increased, while collagenolytic activity, phospholipase A2 and N-acetylglucosaminidase (NAG) decreased.
      These results give an insight into the mechanism of the anti-inflammatory and chondroprotective actions demonstrated by this drug in a number of clinical trials in, patients with osteoarthritis.



      1. L'Hirondel JL, Etude clinique en double insu du sulfate de chondroïtine per os versus placebo dans la gonarthrose fémoro-tibiale (125 patients), Litera Rheumatol 14: 77–84.

        • Uebelhart D
        • Chantraine A
        Efficacité clinique du sulfate de chondroitine dans la gonarthrose: étude randomisée en doublée-insu versus placébo.
        Rev Rhum. 1994; 10: 692
        • Morreale P
        • Manopulo R
        • Galati M
        • Boccanera L
        • Saponati G
        • Bocchi L
        Comparison of the anti-inflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis.
        J Rheum. 1996; 23: 1385-1391
        • Palmieri L
        • Conte A
        • Giovannini L
        • Lualdi P
        • Ronca G
        Metabolic fate of exogenous chondroitin sulfate in the experimental animal.
        Arzneim-Forsch/Drug Res. 1990; 40: 319-323
        • Dawes J
        • Pepper DS
        Catabolism of low dose-heparin in man.
        Thromb Res. 1979; 14: 845-860
        • Dupuy JC
        • Harmand MF
        • Blanquet P
        ACS marqué au 99mTc et scintigraphie du cartilage.
        Isotop Radioact en Clinique Recherche. 1976; 12: 183
        • Otterness IG
        • Moore PF
        Carrageenan foot edema test.
        Meth Enzymol. 1988; 162: 320-327
        • Bailey PJ
        Sponge implants as models.
        Meth Enzymol. 1988; 162: 327-334
        • Bliven ML
        • Otterness IG
        Carrageenan pleurisy.
        Meth Enzymol. 1988; 162: 334-339
        • Conte A
        • Petrini M
        • Vaglini F
        • Polidori R
        Certains mécanismes biochimiques de l'activité antiinflammatoire du sulfate de chondroïtine exogène.
        Litera Rheumatol. 1992; 14: 35-41
        • Bellavite P
        • Dri P
        • Berton G
        • Zabucchi G
        Un nuovo test di funzionalitá fagocitaria basato sulla missura della produzione di anione superossido. I principi generali ed esecuzione.
        Lab J Res Lab Med. 1980; VII: 67-70
        • Demetriou JA
        • Drewes PA
        • Gin JB
        in: Henry RJ Cannon DC Winkelmann JW Clinical Chemistry: Principles and Technics. 2nd ed. Harper and Row, Hagerstown1974: 950-952
        • McFaul SJ
        • Everse J
        Continous assay for cytolytic activity.
        Meth Enzymol. 1986; 162: 491-498
        • Lowry OH
        • Rosenbrough NJ
        • Farr AL
        • Randall RJ
        Protein measurement with Folin phenol reagent.
        J Biol Chem. 1951; 193: 265-269
        • Tengblad A
        Quantitative analysis of hyaluronate in nanogram amounts.
        Biochem J. 1980; 185: 101-105
        • Gisslow MT
        • McBride BC
        A rapid sensitive collagenase assay.
        Anal Biochem. 1975; : 70-78
        • Pruzanski W
        • Vadas P
        • Kim J
        • Jacobs H
        • Stefanski E
        Phospholipase A2 activity associated with synovial fluid.
        J Rheum. 1988; 15: 791-794
        • Marhun D
        Rapid colorimetric assay of β-galactosidase and N-acetyl-β-glucosaminidase in human urine.
        Clin Chim Acta. 1976; 73: 453-461
        • Kragh AM
        in: Alexander P Block RJ Laboratory manual of analytical methods of protein chemistry. Vol. 3. Pergamon Press, Oxford1961: 173-209
        • Sundblad L
        The chemistry of synovial fluid with special regard to Hyaluronic acid.
        Acta Orthop Scand. 1951; 20: 105-113
        • Conte A
        • de Bernardi M
        • Palmieri L
        • Lualdi P
        • Mautone G
        • Ronca G
        • Ronca G
        Metabolic fate of exogenous chondroitin sulfate in man.
        Arzneim-Forsch/Drug Res. 1991; 41: 768-772
        • Conte A
        • Palmieri L
        • Segnini D
        • Ronca G
        Metabolic fate of partially depolymerized chondroitin sulfate administered to rat.
        Drugs Exptl Clin Res. 1991; XVII: 27-33